Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Steve L. McAfee"'
Autor:
Amir T. Fathi, Haesook T. Kim, Robert J. Soiffer, Mark J. Levis, Shuli Li, Annette S. Kim, Zachariah DeFilipp, Areej El-Jawahri, Steve L. McAfee, Andrew M. Brunner, Philip C. Amrein, Alice S. Mims, Laura W. Knight, Devon Kelley, AJ S. Bottoms, Lindsey H. Perry, Jonathan L. Wahl, Jennifer Brock, Elayne Breton, Dylan M. Marchione, Vincent T. Ho, Yi-Bin Chen
Publikováno v:
Clinical Cancer Research. 29:2034-2042
Purpose: Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use in patients with IDH1-mutated AML. Patients and Methods: We conducted a multicent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6018d58039b44e1e6368f3333c96f2a6
https://doi.org/10.1158/1078-0432.ccr-23-0182
https://doi.org/10.1158/1078-0432.ccr-23-0182
Autor:
Yi-Bin Chen, Vincent T. Ho, Dylan M. Marchione, Elayne Breton, Jennifer Brock, Jonathan L. Wahl, Lindsey H. Perry, AJ S. Bottoms, Devon Kelley, Laura W. Knight, Alice S. Mims, Philip C. Amrein, Andrew M. Brunner, Steve L. McAfee, Areej El-Jawahri, Zachariah DeFilipp, Annette S. Kim, Shuli Li, Mark J. Levis, Robert J. Soiffer, Haesook T. Kim, Amir T. Fathi
Representativeness of Study Participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41242f9d5f686fdbc7c3a194abe99cc1
https://doi.org/10.1158/1078-0432.22651561.v1
https://doi.org/10.1158/1078-0432.22651561.v1
Autor:
Yi-Bin Chen, Vincent T. Ho, Dylan M. Marchione, Elayne Breton, Jennifer Brock, Jonathan L. Wahl, Lindsey H. Perry, AJ S. Bottoms, Devon Kelley, Laura W. Knight, Alice S. Mims, Philip C. Amrein, Andrew M. Brunner, Steve L. McAfee, Areej El-Jawahri, Zachariah DeFilipp, Annette S. Kim, Shuli Li, Mark J. Levis, Robert J. Soiffer, Haesook T. Kim, Amir T. Fathi
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c462541a9f1c003172c988b6c6e5ad9f
https://doi.org/10.1158/1078-0432.22651564.v1
https://doi.org/10.1158/1078-0432.22651564.v1
Autor:
Yi-Bin Chen, Vincent T. Ho, Dylan M. Marchione, Elayne Breton, Jennifer Brock, Jonathan L. Wahl, Lindsey H. Perry, AJ S. Bottoms, Devon Kelley, Laura W. Knight, Alice S. Mims, Philip C. Amrein, Andrew M. Brunner, Steve L. McAfee, Areej El-Jawahri, Zachariah DeFilipp, Annette S. Kim, Shuli Li, Mark J. Levis, Robert J. Soiffer, Haesook T. Kim, Amir T. Fathi
Purpose:Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use in patients with IDH1-mutated AML.Methods:We conducted a multicenter, phase I tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a1db0aac1a12c611677a4617ca41ca4
https://doi.org/10.1158/1078-0432.c.6604888.v1
https://doi.org/10.1158/1078-0432.c.6604888.v1
Autor:
Yi-Bin Chen, Vincent T. Ho, Dylan M. Marchione, Elayne Breton, Jennifer Brock, Jonathan L. Wahl, Lindsey H. Perry, AJ S. Bottoms, Devon Kelley, Laura W. Knight, Alice S. Mims, Philip C. Amrein, Andrew M. Brunner, Steve L. McAfee, Areej El-Jawahri, Zachariah DeFilipp, Annette S. Kim, Shuli Li, Mark J. Levis, Robert J. Soiffer, Haesook T. Kim, Amir T. Fathi
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccfeb07ae50aeff720c8e7893ef44bfe
https://doi.org/10.1158/1078-0432.22651567.v1
https://doi.org/10.1158/1078-0432.22651567.v1